Biocon Limited operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biocon Limited with three other
pharmaceutical manufacturers in Asia:
Tonghua Dongbao Medicines Company Limited
sales of 2.54 billion Chinese Renmimbi [US$404.87 million]
of which 89%
Yifan Pharmaceutical Co Ltd
(4.37 billion Chinese Renmimbi [US$696.71 million]
of which 50%
was Health Products - Medicine), and
Samsung Biologics Co Ltd
based in South Korea
(464.63 billion Korean Won [US$433.96 million]
of which 100%
was Biological Medicine Production).
Biocon Limited reported sales of 38.91 billion Indian Rupees (US$594.17 million)
March of 2017.
increase of 11.6%
versus 2016, when the company's sales were 34.85 billion Indian Rupees.
Sales at Biocon Limited have increased during each of the previous five years
(and since 2012, sales have increased a total of 86%).